1. Academic Validation
  2. 5-HT promotes bronchopulmonary dysplasia via TGM2-mediated serotonylation

5-HT promotes bronchopulmonary dysplasia via TGM2-mediated serotonylation

  • iScience. 2025 Nov 19;28(12):114120. doi: 10.1016/j.isci.2025.114120.
Pengpeng Cai 1 2 Ruidong Ding 1 Chunyu Yin 1 Xu Chen 1 Yu Mao 1 Keyu Lu 1 Beibei Wang 1 Yang Yang 1 Mingshun Zhang 1 3 Rui Cheng 1
Affiliations

Affiliations

  • 1 Department of Neonatal Medical Center, Children's Hospital of Nanjing Medical University, Nanjing, China.
  • 2 Department of Pediatrics, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, Jiangsu, China.
  • 3 NHC Key Laboratory of Antibody Technique, Jiangsu Key Laboratory of Pathogen Biology, Department of Immunology, Nanjing Medical University, Nanjing, China.
Abstract

Bronchopulmonary dysplasia (BPD) is a common chronic lung disease in preterm neonates. Untargeted metabolomics of serum samples revealed that tryptophan metabolism may be involved in the pathogenesis of BPD. Specifically, the serum level of 5-hydroxytryptamine (5-HT), a metabolite of tryptophan, is increased in preterm infants with BPD. Similarly, the pulmonary level of 5-HT is increased in a mouse model of hyperoxia-induced BPD. Administration of 5-HT directly impaired lung maturation. Tryptophan Hydroxylase 1 (TPH1) is the rate-limiting enzyme in the biosynthesis of 5-HT. As expected, the TPH1 inhibitor LP533401 mitigated lung injury in pups exposed to 85% oxygen. Mechanistically, 5-HT promotes post-translational serotonylation via Transglutaminase 2 (TGM2) in alveolar epithelial cells. TGM2 expression is increased in the pulmonary tissues of BPD-like mice. Blocking TGM2 partially reversed BPD-like damage to the lungs. Collectively, our findings highlight the roles of 5-HT and serotonylation in the pathogenesis of BPD.

Keywords

Developmental biology; Metabolomics.

Figures
Products
Inhibitors & Agonists
Other Products